1. Home
  2. TNXP vs MFM Comparison

TNXP vs MFM Comparison

Compare TNXP & MFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

N/A

Current Price

$9.26

Market Cap

199.7M

Sector

Health Care

ML Signal

N/A

Logo MFS Municipal Income Trust

MFM

MFS Municipal Income Trust

N/A

Current Price

$4.89

Market Cap

224.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TNXP
MFM
Founded
2007
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
224.5M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
TNXP
MFM
Price
$9.26
$4.89
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $44.50
N/A
AVG Volume (30 Days)
374.3K
★ 471.9K
Earning Date
11-09-2026
01-01-0001
Dividend Yield
N/A
★ 4.08%
EPS Growth
★ 91.75
N/A
EPS
N/A
★ 0.03
Revenue
★ $13,107,000.00
N/A
Revenue This Year
$319.65
N/A
Revenue Next Year
$101.60
N/A
P/E Ratio
★ N/A
$162.67
Revenue Growth
★ 29.85
N/A
52 Week Low
$9.40
$4.76
52 Week High
$24.64
$5.67

Technical Indicators

Market Signals
Indicator
TNXP
MFM
Relative Strength Index (RSI) 26.70 24.64
Support Level $9.40 N/A
Resistance Level $12.99 $5.63
Average True Range (ATR) 0.50 0.08
MACD -0.18 -0.02
Stochastic Oscillator 3.73 25.58

Price Performance

Historical Comparison
TNXP
MFM

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About MFM MFS Municipal Income Trust

MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but it may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.

Share on Social Networks: